Loading
A phase 2 trial of Ifinatamab deruxtecan in small-cell lung cancer, run by Daiichi Sankyo, active and no longer recruiting.
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) is a phase 2 interventional study registered as NCT05280470 by Daiichi Sankyo, with 187 participants enrolled, started 2022-03-09 and due to reach its primary completion in 2025-03-03. Interventions recorded: Ifinatamab Deruxtecan (I-DXd). Conditions listed: Extensive-stage Small-cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ifinatamab deruxtecan, Extensive-stage small-cell lung cancer, Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Extensive-stage small-cell lung cancer, Antibody-drug conjugate (ADC).
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Antibody-drug conjugate (ADC).
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Antibody-drug conjugate (ADC).
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Antibody-drug conjugate (ADC).
Shares Ifinatamab deruxtecan, Extensive-stage small-cell lung cancer, Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Extensive-stage small-cell lung cancer, Antibody-drug conjugate (ADC).
Shares Ifinatamab deruxtecan, Daiichi Sankyo, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/